Paul K. Audhya - 17 May 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
17 May 2025
Transactions value $
-$32,876
Form type
4
Filing time
20 May 2025, 19:27:28 UTC
Previous filing
25 Feb 2025
Next filing
23 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Audhya Paul K. CHIEF MEDICAL OFFICER C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE /s/ Benjamin L. Palleiko, Attorney-in-Fact 20 May 2025 0001860131

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise +6.45K +6.26% 109K 17 May 2025 Direct F1
transaction KALV Common Stock Sale -$32.9K -2.78K -2.54% $11.84 107K 19 May 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Options Exercise $0 -2.42K -20% $0.00 9.68K 17 May 2025 Common Stock 2.42K Direct F1, F3
transaction KALV Restricted Stock Unit Options Exercise $0 -4.03K -33.33% $0.00 8.06K 17 May 2025 Common Stock 4.03K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") and performance stock unit ("PSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 17, 2022, subject to continued service through each vesting date.
F4 1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, subject to continued service through each vesting date.